REPLIGEN CORP Increase (Decrease) in Contract with Customer, Asset
REPLIGEN CORP (RGEN) reported Increase (Decrease) in Contract with Customer, Asset of -$456.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2021-02-24
- REPLIGEN CORP increase (decrease) in contract with customer, asset for the quarter ending 2020-12-31 was $0.00.
- REPLIGEN CORP increase (decrease) in contract with customer, asset for the quarter ending 2019-12-31 was -$99.00K.
- REPLIGEN CORP increase (decrease) in contract with customer, asset for the quarter ending 2019-09-30 was $95.00K.
- REPLIGEN CORP increase (decrease) in contract with customer, asset for the quarter ending 2019-06-30 was $460.00K.
- REPLIGEN CORP increase (decrease) in contract with customer, asset for fiscal 2020 was -$456.00K.
- REPLIGEN CORP increase (decrease) in contract with customer, asset for fiscal 2019 was -$2.15M, a 182.48% decline from fiscal 2018.
- REPLIGEN CORP increase (decrease) in contract with customer, asset for fiscal 2018 was $2.60M.
- REPLIGEN CORP increase (decrease) in contract with customer, asset for fiscal 2017 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$456.00K 10-K · filed 2021-02-24 | ||
| 2020-09-30 | -$456.00K 10-Q · filed 2020-11-05 | |||
| 2019-12-31 | -$99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$4.00K derived: sum of 2 quarters · filed 2021-02-24 | $456.00K derived: sum of 3 quarters · filed 2021-02-24 | -$2.15M 10-K · filed 2021-02-24 |
| 2019-09-30 | $95.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $555.00K derived: sum of 2 quarters · filed 2020-11-05 | -$2.05M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $460.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$2.14M 10-Q · filed 2020-07-30 | ||
| 2019-03-31 | -$2.60M 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | $2.60M 10-K · filed 2021-02-24 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |